



**PRESS RELEASE**

**Bianalisi continues its strategy of consolidating its healthcare platform for integrated diagnostics in Italy by strengthening its capital structure with €470 million in new financing**

**Milan, 28 February 2025 – Bianalisi, the leading independent platform of integrated healthcare diagnostics in Italy,** announces that it has secured €470 million in new financing to further develop its integrated healthcare platform across the national territory. The transaction will enable Bianalisi to continue investing in the consolidation of the Italian healthcare sector, which is the most fragmented in Europe. In particular, the transaction accelerates the M&A strategy of the Group, that is focused on the careful selection of highly accretive and synergic clinical laboratories, outpatient care centers and diagnostic imaging centers. The primary goal is to further strengthen the capillarity of Bianalisi's network and expand the range of services offered to the benefit of its patients, in parallel to achieving a substantial organic growth through the increasing integration of its network across Italy.

With a capillary presence in 13 regions, Bianalisi has developed a unique healthcare platform, offering a full range of healthcare services in laboratory diagnostics, outpatient diagnostics (covering all major medical specialties) and imaging diagnostics (including advanced tests such as CT scans and MRIs). Thanks to its territorial proximity and healthcare offering for integrated diagnostics, combined with the outstanding level of its doctors and the high quality of the services offered that meet the highest industry standards, Bianalisi is a key reference point for patients welcoming over 15,000 patients daily at its facilities.

Bianalisi boasts over 30 years of experience, marked by a solid growth path, both organic and through M&A. In 2024, the Bianalisi Group reached €210 million revenues, recording a significant growth compared to the €130 million of 2021, the year in which Charme IV fund invested in the company, supporting and further accelerating Bianalisi expansion. During the same period, the number of Bianalisi labs and sample collection points increased from 260 to 350, the outpatient care centers grew from 50 to over 70 and the diagnostic imaging centers were expanded from 15 to 46, with the number of doctors operating within Bianalisi's network also growing from 600 to over 1,500. Over the period 2021-2024, Bianalisi completed more than 60 acquisitions, demonstrating the effectiveness of its M&A expertise and know-how and confirming the quality of its consolidation strategy in Italy.

The new financing was structured with a pool of primary international lenders, including funds of Carlyle and Arcmont, along with Natixis. The transaction consists of €470 million financing – issued in the form of a private placement – with maturity date in January 2032.

\* \* \*



**Giuliano Caslini, founder and Chairman of Bianalisi,** commented: *“This transaction represents another significant milestone of Bianalisi’s journey, fully aligned with the Group’s long-term strategy, which has supported our substantial growth over the past twenty years. This strategy, unparalleled within this sector, has positioned Bianalisi as the largest independent healthcare platform of integrated diagnostics in Italy, with proven M&A track-record and know-how and a highly qualified management team to continue the development of the Bianalisi platform, through both organic growth and M&A”.*

**Giovanni Gianolli, CEO of Bianalisi,** commented: *“Thanks to this transaction, Bianalisi has secured the financial resources necessary to support the growth outlined in our strategic plan. It is our firm intention to continue investing in the expansion of our network of facilities for healthcare diagnostics, the broadening of our service offerings – including diagnostics as well as therapeutic care and prevention – consolidating our integrated healthcare model, and responding ever more efficiently and effectively to our patients’ health and prevention needs”.*

**Tommaso Beolchini, co-founder of Charme and vice Chairman of Bianalisi,** commented: *“We are extremely pleased to announce this significant transaction on Bianalisi’s capital structure, further confirming the solid reputation built not only among our patients and the 1,500 physicians collaborating with Bianalisi but also with our new partners Carlyle and Arcmont, as well as Natixis, who have chosen to support Bianalisi in its remarkable consolidation project in such a high-growth sector”.*